Biogen and Eisai Reports Results of Long-Term Extension P-Ib study for aducanumab

 Biogen and Eisai Reports Results of Long-Term Extension P-Ib study for aducanumab

Biogen and Eisai Reports Results of Long-Term Extension P-Ib study for aducanumab

Shots:
  • The data included results from the ongoing long-term extension (LTE) P-1b study of aducanumab for the treatment of Alzheimer Disease
  •  The results for each dose are same as interimanalyses showing decreasing level of amyloid plaque when measured with PET, in dose and time-dependent manner in titration and FD cohorts
  • The study (N=196) patients receives aducanumab or PBO and (143/196) entered into LTE cohorts with six arms: PBO switchers, 1mg/kg switcher to 3 mg/kg, FD (3, 6, 10 mg/kg) and titration, having a duration of 36 mos in titration and 48 mos in FD cohorts
Click here to read full press release/ article | Ref: Biogen | Image:  Xconomy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post